| |
Weight GAIN - ARTs, Integrase
|
| |
| |
We assessed the association between the specific third agent drug and ≥10% weight gain (Table5). Compared to EFV, the initiation of BICor DTG (OR 1.82, 95% CI 1.24-2.66, p=0.002), EVG/c (OR 1.36, 95% CI 1.04-1.78, p=0.026), RPV (OR 1.51, 95% CI 1.03-2.20, p=0.035), but not ATV/r, were associated with an increased risk of ≥10% weight gain. Among the NRTIs, TAF (OR 1.75, 95% CI 1.04-2.95, p=0.034), but not ABC or TDF, were associated with increased risk for ≥10% weight gain compared to AZT. TAF was also associated with an increased risk of ≥10% weight gain compared to ABC (OR 1.90, 95% CI 1.25-2.88, p = 0.003) and TDF (OR 1.47, 95% CI 1.14-1.90, p = 0.003)
http://natap.org/2019/EACS/ciz999.pdf
http://natap.org/2019/EACS/EACS_46.htm
Hepatic steatosis in HIV+ individuals: which impact has baseline BMI and treatment with integrase inhibitors? (01/13/20)
http://natap.org/2019/EACS/EACS_108.htm
Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes (12/12/19)
|
|
| |
| |
|
|
|
